1
|
rDKK-1
Dickkopf-1
|
31
|
16
|
6.07
|
66.99
|
-0.578
|
0.046
|
0. 510
|
No
|
Yes
|
No
|
(Malaei et al., 2019)
|
2
|
TSH (SR95-1)
Thyroid-stimulating hormone
|
35
|
27
|
6.14
|
67.42
|
-0.743
|
-0.011
|
0.643
|
No
|
Yes
|
No
|
(Mard-Soltani et al., 2018)
|
3
|
TSH (SR95-2)
Thyroid-stimulating hormone
|
25
|
7
|
8.31
|
53.94
|
-0.852
|
-0.043
|
0.546
|
No
|
Yes
|
No
|
(Mard-Soltani et al., 2018)
|
4
|
TSH
Thyroid-stimulating hormone
|
32
|
0
|
8.53
|
24.11
|
-1.140
|
-0.116
|
0.722
|
No
|
Yes
|
No
|
(Mard-Soltani, Rasaee, Sheikhi, & Hedayati, 2017)
|
5
|
IpaD
invasive plasmid antigen
|
19
|
40
|
5.40
|
83.71
|
-0.398
|
0.107
|
0.625
|
Yes
|
Yes
|
Yes
|
(Hesaraki et al., 2013)
|
6 |
c-terminal of GRP78 |
28 |
33 |
4.59 |
84.81 |
-0.642 |
-0.034 |
0.951 |
No |
Yes |
Yes |
(Aghamollaei et al., 2017) |
7
|
IpaC
invasive plasmid antigen
|
45
|
58
|
7.83
|
92.29
|
-0.433
|
0.105
|
0.530
|
Yes
|
Yes
|
Yes
|
(Malaei et al., 2013)
|
8
|
HTLV-I (human T-cell lymphotropic virus type
I)
|
30
|
16
|
5.16
|
99.70
|
0.082
|
0.223
|
0.449
|
No
|
Yes
|
Yes
|
(Heydari-Zarnagh, Hassanpour, & Rasaee, 2015)
|
9 |
Chimeric HBV/HLV-I |
27 |
19 |
6.47 |
100.33 |
0.096 |
0.267 |
0.284 |
No |
No |
No |
(HEYDARI, Ravanshad, POURFATHOLLAH, & Rasaee,
2015) |
10
|
GST /NuMA
(The Nuclear Mitotic Apparatus)
|
63
|
61
|
5.50
|
91.07
|
-0.484
|
0.062
|
0.679
|
Yes
|
Yes
|
Yes
|
(Soukhtehzari, Rasaee, & Javanmardi, 2019)
|
11
|
Hepatitis B virus (HBV)
HBsAg
|
17.9
|
23
|
8.20
|
62.50
|
0.253
|
0.298
|
0.538
|
No
|
Yes
|
Yes
|
(Khalili et al., 2017)
|
12
|
EM-L2 peptide
EGFR: epidermal growth factor receptor
|
28
|
18
|
8.06
|
92.93
|
-0.305
|
0.140
|
0.406
|
Yes
|
Yes
|
No
|
(Asadi-Ghalehni et al., 2015)
|
13 |
truncated BBK32 protein of Borrelia afzelii
|
35 |
47 |
4.99 |
79.91 |
-0.957 |
-0.107 |
0.859 |
Yes |
No |
Yes |
(Ranka,
Capligina, Brangulis, Sondore, & Baumanis, 2009) |
14 |
rSap2t (secreted aspartyl proteinase2) |
43.4 |
20 |
4.65 |
86.10 |
-0.157 |
0.168 |
0.517 |
No |
No |
Yes |
(Sandini et al.,
2011) |
15 |
human cardiac ryanodine receptor (RyR2) |
25.4 |
33 |
5.05 |
82.20 |
-0.251 |
0.114 |
0.613 |
No |
No |
No |
(Bauerová-Hlinková et al.,
2010) |
16 |
human cardiac ryanodine receptor (RyR2) |
43.3 |
58 |
6.64 |
104.13 |
-0.255 |
0.154 |
0.472 |
No |
Yes |
Yes |
(Bauerová-Hlinková et al.,
2010) |
17 |
MBP/ ALDH3A1 |
92 |
33 |
9.42 |
76.48 |
-0.459 |
0.070 |
0.368 |
No |
No |
Yes |
(Voulgaridou, Mantso, Chlichlia, Panayiotidis, & Pappa,
2013) |
18 |
His/ALDH3A1 Aldehyde dehydrogenase 3A1 |
51 |
38 |
7.63 |
88.82 |
-0.259 |
0.159 |
0.323 |
Yes |
No |
No |
(Voulgaridou et al.,
2013) |
19 |
NusA |
54.8 |
51 |
5.70 |
100.32 |
-0.375 |
0.113 |
0.630 |
Yes |
No |
Yes |
(Harrison, 2000) |
20 |
BFR bacterioferritin |
18.5 |
63 |
4.69 |
104.94 |
-0.472 |
0.007 |
0.749 |
No |
Yes |
Yes |
(Harrison, 2000) |
21 |
hIFN-\(\gamma\) (human interferon-\(\gamma\)) |
17.1 |
51 |
9.70 |
67.71 |
-0.847 |
0.088 |
0.784 |
Yes |
No |
No |
(Harrison,
2000) |
22 |
NusA/hIFN-γ |
72 |
55 |
8.33 |
92.96 |
-0.482 |
-0.083 |
0.62 |
Yes |
No |
Yes |
(Harrison, 2000) |
23 |
CGTase (Cyclodextrin glycosyltransferase) |
92 |
16 |
4.23 |
73.39 |
-0.483 |
0.001 |
0.497 |
No |
Yes |
Yes |
(Hao et al.,
2017) |
24 |
EMA-1 (Equi Merozoite Antigen 1) |
34 |
42 |
5.65 |
100.26 |
0.014 |
0.216 |
0.643 |
Yes |
Yes |
Yes |
(Baldani, Hilario, Nakaghi,
Bertolini, & Machado, 2011) |
25 |
WT moPrP |
23 |
18 |
9.38 |
54.06 |
-0.609 |
0.022 |
0.439 |
Yes |
Yes |
No |
(Sengupta & Udgaonkar, 2017) |
26 |
lipase lipPN1 |
31 |
44 |
6.51 |
91.08 |
-0.134 |
0.193 |
0.404 |
No |
No |
No |
(Shao, Hu, Sun, & Zhou, 2019) |
27 |
GST/Saccharomyces cerevisiae Polo-like Kinase, Cdc5 |
107 |
35 |
9.06 |
84.07 |
-0.488 |
0.069 |
0.334 |
No |
No |
Yes |
(Chauhan,
Samanta, Thakur, & Sourirajan, 2015) |
28. |
CheW Protein from Thermotoga petrophila RKU-1 |
17 |
39 |
5.01 |
123.65 |
0.122 |
0.104 |
0.862 |
Yes |
Yes |
Yes |
(Grishin
et al., 2018) |
29 |
Trehalase |
71 |
36 |
5.86 |
81.61 |
-0.404 |
0.246 |
0.339 |
No |
No |
Yes |
(Ai et al., 2018) |
30 |
H. influenzae IgA protease |
130 |
24 |
6.59 |
69.32 |
-0.683 |
-0.017 |
0.515 |
No |
Yes |
Yes |
(Wang et al., 2018) |
31
|
nucleocapsid protein of MERS
coronavirus
|
45
|
22
|
10
|
56.76
|
-0.864
|
-0.082
|
0.501
|
Yes
|
Yes
|
Yes
|
(Yangbo et al., 2015)
|
32
|
Lumazine
synthase [Brucella melitensis]
|
17.5
|
49
|
6.59
|
94.49
|
0.127
|
0.268
|
0.514
|
Yes
|
No
|
No
|
(Majidi, Najafi, & Saeedian, 2019)
|
33 |
VEGF121 (Vascular Endothelial Growth Factor) |
16 |
9 |
6.07 |
55.54 |
-0.794 |
-0.029 |
0.614 |
No |
No |
No |
(Kazemi-Lomedasht et al., 2014) |
34 |
Neurotoxin type E |
50 |
12 |
9 |
84.13 |
-0.562 |
0.047 |
0.483 |
No |
No |
Yes |
(Mousavi, NAZARIAN, AMANI, MONTASER, & RASOULI,
2004) |
35 |
C-terminal heavy chain of C. botulinum neurotoxin type E |
11 |
0 |
8 |
50.34 |
-0.711 |
0.010 |
0.611 |
Yes |
Yes |
No |
(Mansour
et al., 2010) |
36 |
Endostatin, a C-terminal fragment of collagen XVIII, |
20 |
29 |
9.30 |
78.34 |
-0.224 |
0.145 |
0.280 |
Yes |
No |
Yes |
(Yari, Afzali,
Mozafari, Mansouri, & Mostafaie, 2013) |
37 |
botulinum neurotoxin serotypes A, B and E binding subdomains |
20 |
25 |
6.12 |
62.26 |
-0.614 |
0.040 |
0.538 |
No |
Yes |
No |
(Ebrahimi,
Rasaee, Mousavi, & Babaeipour, 2010) |
38 |
Smallest Isoform of Human Interleukin-24 |
27 |
40 |
8.94 |
95.12 |
0.000 |
0.219 |
0.415 |
No |
Yes |
Yes |
(Valiyari et al.,
2017) |
39 |
single-domain antibody |
15 |
12 |
8.02 |
59.20 |
-0.482 |
0.084 |
0.564 |
Yes |
No |
Yes |
(Zarschler, Witecy, Kapplusch, Foerster, &
Stephan, 2013) |
40 |
MUC1/HER2 |
33 |
19 |
5.40 |
61.63 |
-0.467 |
0.061 |
0.483 |
No |
Yes |
No |
(Gheybi, Amani, Salmanian, Mashayekhi, & Khodi,
2014) |